LAEKNA-B has entered into a new licensing arrangement concerning its proprietary drug candidate.

On June 9, 2026, the company executed an exclusive licensing agreement with VASQUE BIO, Inc. Under the terms of this deal, LAEKNA-B has granted VASQUE BIO a global exclusive license, excluding mainland China, Hong Kong, Macau, and Taiwan, to develop, manufacture, commercialize, and otherwise utilize LAE118. LAE118 is a novel, internally developed PI3K α pan-mutant selective inhibitor.

In return for these rights, LAEKNA-B is entitled to receive a one-time, non-refundable, and non-creditable upfront cash payment of $10 million. Additionally, the company has the right to receive, at no extra cost, equity in VASQUE BIO amounting to up to a high double-digit percentage of its issued ordinary shares, or a cash payment in lieu of such shares.

The agreement also stipulates that LAEKNA-B is eligible to receive development and sales milestone payments totaling up to $517 million. Furthermore, the company will earn tiered royalty payments ranging from single-digit to double-digit percentages based on the future net sales of LAE118 within the licensed territory.

Should VASQUE BIO enter into a qualifying strategic collaboration or acquisition transaction linked to the use of LAE118, LAEKNA-B would be entitled to an additional payment, which could be as high as 50% of the value of that strategic transaction.

The company's board of directors believes the execution of this licensing agreement is in the best interests of the company and its shareholders as a whole. VASQUE BIO primarily focuses on developing treatments for rare diseases, while LAEKNA-B will concentrate on developing LAE118 for oncology therapies outside the licensed region.

This partnership presents an opportunity for LAEKNA-B to accelerate the global development and commercialization of LAE118 for a broader range of indications within the licensed territory, thereby speeding up downstream value creation through avenues such as licensing, collaboration, or merger and acquisition exits.

The upfront and potential milestone payments are expected to strengthen the company's financial position, supporting its future growth initiatives. The right to acquire equity in VASQUE BIO also allows LAEKNA-B to retain a stake in LAE118's future appreciation potential.

Currently, LAEKNA-B is actively engaged in discussions with several potential partners and intends to pursue strategic collaborations to accelerate the clinical development and commercialization of its portfolio of candidate drug assets. The company aims to maintain a robust financial standing, which will provide flexibility in evaluating potential partnership structures to align interests and maximize the potential of its assets.